We are scientific pioneers, on a journey to cure cancer and infectious disease

Curious how our Accum™ Technology has 10x the impact on infected cells vs. other approved solutions?

 

News & Media

Defence Therapeutics Speaks on its Vaccine Development

Defence Therapeutics announces clinical trials for 2023

Defence Financing

Defence Financing

Vancouver, BC, Canada, January 19th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news release...

read more
Defence’s Accutox® Impairs Lung Cancer Growth

Defence’s Accutox® Impairs Lung Cancer Growth

Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it...

read more

Innovating Pathways
to Success

Current treatments for cancer and infectious diseases aren’t working. Too many people are dying in search of effective treatments for improved health.

Leading the way with targeted science, strategic products and bold curiosity, Defence Therapeutics are proudly uncovering micro and macro level methods for bringing catalytic change to future patients. How?

Accum™ Technology

A scalable delivery platform with enormous mulitplier effect offering a diversified investment opportunity. Currently supported with our two major programs:

 
 

01

CANCER THERAPEUTICS

Learn More

02

VACCINE DEVELOPMENT

Learn More

See Accum™ Technology in action

DRUG THE

UNDRUGGABLE®

  • Accum™ empowers vaccine development to become entirely scalable across multiple indications.
  • This patented platform technology is supporting Defence Therapeutics vaccine development priorities:

    • Various cancers
    • Infectious diseases
  • With drug delivery enhanced by 10x over current solutions (ADC’s), our Accum™ platform is the perfect partner for current and future drug treatments.
  • Accum™ is a global solution, and when paired with effective vaccines has the potential to become the therapeutic standard for human diseases.

First-of-its-kind breakthrough, offering precision and efficient cell nucleus drug delivery.

Proprietary and scalable technology targeted at viruses and infectious disease.

Problem-driven solutions confirming strong market potential and upside.

Fully owned assets to be capitalized via global licensing deals.

Exponential scaling potential through partner collaborations.

Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.

Aggressive, accelerated growth model with two innovative and proprietary pathways to market.

First-of-its-kind breakthrough, offering precision and efficient cell nucleus drug delivery.

Proprietary and scalable technology targeted at viruses and infectious disease.

Problem-driven solutions confirming strong market potential and upside.

Fully owned assets to be capitalized via global licensing deals.

Exponential scaling potential through partner collaborations.

Proven ability as showcased via flourishing partner pubco’s: world-class and award-winning researchers, University level facilities, a leading global health care system and a sophisticated investor community.

Aggressive, accelerated growth model with two innovative and proprietary pathways to market.

Learn more about our biopharmaceutical innovations for future generations:

Corporate Deck

Sign up for our newsletter

Stay up to date with Defence Therapeutics